表纸
市场调查报告书

重症肌无力:开发平台分析

Myasthenia Gravis - Pipeline Review, H1 2019

出版商 Global Markets Direct 商品编码 200977
出版日期 内容资讯 英文 152 Pages
订单完成后即时交付
价格
Back to Top
重症肌无力:开发平台分析 Myasthenia Gravis - Pipeline Review, H1 2019
出版日期: 2019年02月01日内容资讯: 英文 152 Pages
简介

重症肌无力是由于末梢神经的自体免疫性神经肌肉障碍,由于对尼古丁性乙醯胆鹼(ACh)突触后受体的抗体,产生肌肉无力和易疲劳感的难治之症。由于肌肉无力,产生呼吸困难和咀嚼、吞咽困难、头部下垂、脸筋的脆弱化、嘶哑声音、复视、眼睑下垂等症状。治疗选项有,抑制自体免疫反应的医药品,及免疫球蛋白的静脉注射等。

本报告提供全球各国的重症肌无力治疗用的开发中产品的开发情形相关分析,开发中产品的最新趋势,及临床实验的各阶段的产品一览,主要企业简介,主要药物概要(产品概要、功能机制、研究开发(R&D)的发展情形),最新的产业趋势等调查,并将其结果,为您概述为以下内容。

简介

  • 分析范围

重症肌无力概要

治疗药的开发

  • 重症肌无力开发中产品:概要
  • 重症肌无力开发中产品:比较分析

各企业开发中的重症肌无力治疗药

大学/研究机关研究中的重症肌无力治疗药

开发中产品的概要

  • 后期阶段的产品
  • 临床实验阶段的产品
  • 初期阶段的产品

重症肌无力治疗药:开发中的产品一览(各企业)

重症肌无力治疗药:研究中的产品一览(各大学/研究机关)

重症肌无力开发治疗药的企业

  • Achillion Pharmaceuticals, Inc.
  • Akari Therapeutics, Plc
  • Alexion Pharmaceuticals, Inc.
  • arGEN-X BV
  • Baxalta Incorporated
  • Biokine Therapeutics Ltd.
  • BioMarin Pharmaceutical Inc.
  • CuraVac, Inc.
  • GlaxoSmithKline Plc
  • Grifols, S.A.
  • HanAll Biopharma Co., Ltd.
  • Karus Therapeutics Limited
  • Lead Discovery Center GmbH
  • Neurotune AG
  • Novartis AG
  • Pfizer Inc.
  • ReceptoPharm, Inc.
  • Regenesance BV
  • Toleranzia AB

重症肌无力:治疗药的评估

  • 单剂治疗药的情况
  • 各标的
  • 各行动机制
  • 各投药法
  • 各分子类型

药物简介

  • amifampridine phosphate
  • ARGX-113
  • BB-008
  • belimumab
  • BKT-130
  • CFZ-533
  • Coversin
  • CVMG-01
  • eculizumab
  • GL-2045
  • HL-161
  • 免疫球蛋白(人类用)
  • KA-1463
  • 重症肌无力用 C1q 阻碍单株抗体
  • NT-1654
  • 重症肌无力用重组蛋白
  • regenemab
  • RPI-78M
  • SM-201
  • 自体免疫障碍、病毒感染用免疫蛋白酶体次单元LMP7阻碍小分子
  • 重症肌无力用补体D因素阻碍小分子
  • 重症肌无力用疫苗

重症肌无力治疗药:最新开发平台趋势

重症肌无力治疗药:开发暂停的产品

重症肌无力治疗药:开发中止的产品

重症肌无力相关产品的开发里程碑

  • 值得注意的最新趋势、新闻稿

附录

图表一览

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: GMDHC11088IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Myasthenia Gravis - Pipeline Review, H1 2019, provides an overview of the Myasthenia Gravis (Immunology) pipeline landscape.

Myasthenia gravis is autoimmune neuromuscular disease characterized by weakness and rapid fatigue of any of the muscles under voluntary control. Symptoms include drooping of one or both eyelids, diplopia and difficulty swallowing, chewing and speaking. Treatment includes immunosuppressants, corticosteroids and surgery.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Myasthenia Gravis - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Myasthenia Gravis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Myasthenia Gravis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Myasthenia Gravis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 6, 5, 15 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.

Myasthenia Gravis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Myasthenia Gravis (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Myasthenia Gravis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Myasthenia Gravis (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Myasthenia Gravis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Myasthenia Gravis (Immunology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Myasthenia Gravis (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Myasthenia Gravis (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Myasthenia Gravis - Overview
  • Myasthenia Gravis - Therapeutics Development
  • Myasthenia Gravis - Therapeutics Assessment
  • Myasthenia Gravis - Companies Involved in Therapeutics Development
  • Myasthenia Gravis - Drug Profiles
  • Myasthenia Gravis - Dormant Projects
  • Myasthenia Gravis - Discontinued Products
  • Myasthenia Gravis - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Myasthenia Gravis, H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products under Development by Universities/Institutes, H1 2019
  • Products under Development by Companies, H1 2019
  • Products under Development by Companies, H1 2019 (Contd..1), H1 2019
  • Products under Development by Universities/Institutes, H1 2019
  • Number of Products by Stage and Target, H1 2019
  • Number of Products by Stage and Mechanism of Action, H1 2019
  • Number of Products by Stage and Route of Administration, H1 2019
  • Number of Products by Stage and Molecule Type, H1 2019
  • Myasthenia Gravis - Pipeline by Akari Therapeutics Plc, H1 2019
  • Myasthenia Gravis - Pipeline by Alexion Pharmaceuticals Inc, H1 2019
  • Myasthenia Gravis - Pipeline by Alpha Cancer Technologies Inc, H1 2019
  • Myasthenia Gravis - Pipeline by Argenx SE, H1 2019
  • Myasthenia Gravis - Pipeline by BioMarin Pharmaceutical Inc, H1 2019
  • Myasthenia Gravis - Pipeline by Bristol-Myers Squibb Co, H1 2019
  • Myasthenia Gravis - Pipeline by CuraVac Inc, H1 2019
  • Myasthenia Gravis - Pipeline by Grifols SA, H1 2019
  • Myasthenia Gravis - Pipeline by GT Biopharma Inc, H1 2019
  • Myasthenia Gravis - Pipeline by HanAll Biopharma Co Ltd, H1 2019
  • Myasthenia Gravis - Pipeline by Momenta Pharmaceuticals Inc, H1 2019
  • Myasthenia Gravis - Pipeline by Neurotune AG, H1 2019
  • Myasthenia Gravis - Pipeline by Novartis AG, H1 2019
  • Myasthenia Gravis - Pipeline by Pfizer Inc, H1 2019
  • Myasthenia Gravis - Pipeline by Protalex Inc, H1 2019
  • Myasthenia Gravis - Pipeline by Ra Pharmaceuticals Inc, H1 2019
  • Myasthenia Gravis - Pipeline by Toleranzia AB, H1 2019
  • Myasthenia Gravis - Pipeline by Tolerion Inc, H1 2019
  • Myasthenia Gravis - Pipeline by UCB SA, H1 2019
  • Myasthenia Gravis - Dormant Projects, H1 2019
  • Myasthenia Gravis - Discontinued Products, H1 2019

List of Figures

  • Number of Products under Development for Myasthenia Gravis, H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products under Development by Universities/Institutes, H1 2019
  • Number of Products by Top 10 Targets, H1 2019
  • Number of Products by Stage and Top 10 Targets, H1 2019
  • Number of Products by Top 10 Mechanism of Actions, H1 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019
  • Number of Products by Routes of Administration, H1 2019
  • Number of Products by Stage and Routes of Administration, H1 2019
  • Number of Products by Molecule Types, H1 2019
  • Number of Products by Stage and Molecule Types, H1 2019
Back to Top